Belite Bio, a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, announced that its board of directors has appointed Hendrik Scholl as the Chief Medical Officer of the company, effective immediately.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLTE:
- Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer
- Belite Bio price target raised to $60 from $59 at H.C. Wainwright
- BLTE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Belite Bio Advances Novel Retinal Disease Treatment
- Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update